APC Anti-CD79b antibody [EPR6860]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CD79b also known as Ig-beta is a protein that plays a mechanical role as part of the B-cell antigen receptor complex. This protein with a mass of approximately 40 kDa is mainly expressed on the surface of B lymphocytes. It is an important component of the heterodimeric complex composed of CD79a (Ig-alpha) and CD79b which associates with membrane-bound immunoglobulins to form the B-cell receptor (BCR). CD79b is essential for transducing activation signals following antigen binding to the BCR.

Biological function summary

The primary role of CD79b within the immune system is to support signal transduction. Upon binding of an antigen to BCR on B cells CD79b as part of the BCR complex initiates signaling cascades which lead to B-cell activation proliferation and differentiation. These processes are critical for humoral immunity ensuring adequate antibody production. CD79b is often found in association with CD19 another important B-cell surface protein and together they aid in amplifying the signals required for B-cell response.

Pathways

CD79b is deeply involved in the B-cell receptor signaling pathway and the broader adaptive immune response. Once the BCR is engaged by an antigen CD79b helps activate intracellular signaling pathways that involve kinases such as SYK and BLNK which help propagate and amplify the immune response. These pathways also interact with other receptor components like CD22 and CD19 creating a network of interactions ensuring effective pathogen recognition and response.

Associated diseases and disorders

CD79b carries significant relevance in the context of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and some types of lymphoma. Dysregulation or mutations in CD79b can affect BCR signaling leading to unchecked B-cell proliferation characteristic of these diseases. Additionally CD79b's interaction with proteins such as SYK in the signaling pathways makes it a potential therapeutic target in treating B-cell related cancers. Researchers are actively investigating anti-CD79b therapies to disrupt abnormal signaling in B-cell malignancies.